ImmunityBio (IBRX) Fundamental Analysis: Revenue, Earnings & Valuation

0.89 / 10

Underperform

Fundamental rating is Underperform with a 0.9/10 score. Inventory and receivables turnover appear decent, but revenue growth and tax efficiency are poor. Weighted fund‑flow score is 0.89, and key ratios carry negative weights, indicating a challenging financial backdrop.

Analysis Checks(5/10)

Revenue-MV

Value-1.76

Score1/3

Weight53.08%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value668.31

Score0/3

Weight-21.49%

1M Return-2.75%

Inventory turnover ratio

Value0.16

Score2/3

Weight-6.31%

1M Return-0.66%

Accounts receivable turnover ratio

Value5.03

Score2/3

Weight-5.63%

1M Return-0.65%

PB-ROE

Value2.31

Score0/3

Weight41.16%

1M Return3.80%

Income tax / Total profit (%)

Value0.04

Score1/3

Weight-5.16%

1M Return-0.59%

Fixed assets turnover ratio

Value0.71

Score2/3

Weight-8.98%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-6.35%

1M Return-0.73%

Cost of sales ratio (%)

Value0.67

Score3/3

Weight7.91%

1M Return0.79%

Asset-MV

Value-0.55

Score0/3

Weight51.77%

1M Return4.88%

Is IBRX undervalued or overvalued?

IBRX scores 0.89/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -310.25% net margin, -21.59 P/E ratio, -15.19 P/B ratio, and 35.59% earnings growth, these metrics solidify its Underperform investment rating.